Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 11 | 2024 | 73 | 1.190 |
Why?
|
| Enterobacteriaceae Infections | 2 | 2020 | 2 | 0.780 |
Why?
|
| Fever | 2 | 2020 | 7 | 0.700 |
Why?
|
| Headache | 1 | 2020 | 3 | 0.670 |
Why?
|
| Carbapenems | 1 | 2020 | 1 | 0.650 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 5 | 2023 | 14 | 0.580 |
Why?
|
| Staphylococcal Infections | 4 | 2023 | 16 | 0.580 |
Why?
|
| Nevirapine | 1 | 2017 | 2 | 0.520 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2017 | 11 | 0.520 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2017 | 17 | 0.520 |
Why?
|
| Anti-Retroviral Agents | 1 | 2017 | 28 | 0.510 |
Why?
|
| Humans | 23 | 2024 | 6794 | 0.490 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2024 | 7 | 0.410 |
Why?
|
| HIV Infections | 1 | 2017 | 432 | 0.360 |
Why?
|
| Neonatal Sepsis | 2 | 2024 | 2 | 0.360 |
Why?
|
| Cost-Benefit Analysis | 3 | 2021 | 48 | 0.350 |
Why?
|
| Vancomycin | 2 | 2021 | 5 | 0.340 |
Why?
|
| Male | 11 | 2024 | 3671 | 0.320 |
Why?
|
| Female | 13 | 2024 | 4060 | 0.310 |
Why?
|
| Cross Infection | 3 | 2024 | 12 | 0.290 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2021 | 10 | 0.270 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2016 | 4 | 0.270 |
Why?
|
| Adult | 9 | 2024 | 2113 | 0.270 |
Why?
|
| Infant, Newborn | 4 | 2024 | 199 | 0.260 |
Why?
|
| Acinetobacter Infections | 3 | 2018 | 6 | 0.240 |
Why?
|
| Acinetobacter baumannii | 3 | 2018 | 6 | 0.240 |
Why?
|
| Coccidioidomycosis | 2 | 2017 | 3 | 0.230 |
Why?
|
| Bacteremia | 3 | 2019 | 8 | 0.220 |
Why?
|
| Antimicrobial Stewardship | 1 | 2024 | 2 | 0.210 |
Why?
|
| Quality Improvement | 1 | 2024 | 31 | 0.200 |
Why?
|
| Chlorhexidine | 2 | 2023 | 2 | 0.200 |
Why?
|
| Mupirocin | 2 | 2023 | 2 | 0.200 |
Why?
|
| Blood Culture | 1 | 2023 | 2 | 0.200 |
Why?
|
| Influenza, Human | 1 | 2023 | 18 | 0.190 |
Why?
|
| Pregnancy | 3 | 2023 | 599 | 0.180 |
Why?
|
| Child | 2 | 2020 | 524 | 0.170 |
Why?
|
| Young Adult | 6 | 2024 | 567 | 0.170 |
Why?
|
| Fomites | 1 | 2020 | 1 | 0.160 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 27 | 0.160 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 43 | 0.160 |
Why?
|
| Middle Aged | 7 | 2024 | 2108 | 0.150 |
Why?
|
| Disinfection | 1 | 2019 | 1 | 0.150 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2019 | 5 | 0.150 |
Why?
|
| Drug Therapy, Combination | 2 | 2017 | 84 | 0.150 |
Why?
|
| Decision Trees | 1 | 2019 | 6 | 0.150 |
Why?
|
| Fungal Proteins | 1 | 2018 | 2 | 0.140 |
Why?
|
| Virus Diseases | 1 | 2018 | 3 | 0.140 |
Why?
|
| Virus Shedding | 1 | 2018 | 3 | 0.140 |
Why?
|
| Respiratory Tract Infections | 1 | 2018 | 11 | 0.140 |
Why?
|
| Meningitis, Fungal | 1 | 2017 | 1 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 8 | 0.130 |
Why?
|
| False Positive Reactions | 1 | 2017 | 13 | 0.130 |
Why?
|
| Viral Load | 1 | 2017 | 26 | 0.130 |
Why?
|
| HIV | 1 | 2017 | 16 | 0.130 |
Why?
|
| Enterobacteriaceae | 1 | 2016 | 3 | 0.130 |
Why?
|
| Cryptococcus gattii | 1 | 2016 | 1 | 0.130 |
Why?
|
| Listeriosis | 1 | 2016 | 3 | 0.130 |
Why?
|
| Coinfection | 1 | 2016 | 4 | 0.130 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2016 | 4 | 0.130 |
Why?
|
| Bayes Theorem | 3 | 2021 | 25 | 0.120 |
Why?
|
| Molecular Epidemiology | 1 | 2015 | 3 | 0.120 |
Why?
|
| Cat-Scratch Disease | 1 | 2015 | 1 | 0.110 |
Why?
|
| Bartonella henselae | 1 | 2015 | 1 | 0.110 |
Why?
|
| Lymphatic Diseases | 1 | 2015 | 4 | 0.110 |
Why?
|
| Aged | 5 | 2019 | 1539 | 0.110 |
Why?
|
| California | 3 | 2023 | 230 | 0.110 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 497 | 0.100 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 280 | 0.090 |
Why?
|
| Risk Factors | 3 | 2024 | 767 | 0.090 |
Why?
|
| Pneumonia, Bacterial | 1 | 2012 | 3 | 0.090 |
Why?
|
| Diabetes Complications | 1 | 2012 | 41 | 0.090 |
Why?
|
| beta-Lactams | 1 | 2011 | 2 | 0.090 |
Why?
|
| Daptomycin | 1 | 2011 | 2 | 0.090 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2011 | 2 | 0.090 |
Why?
|
| Carrier State | 2 | 2023 | 3 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 231 | 0.090 |
Why?
|
| Area Under Curve | 2 | 2021 | 15 | 0.080 |
Why?
|
| Vaccination | 2 | 2023 | 49 | 0.080 |
Why?
|
| Hospitals | 2 | 2023 | 17 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2015 | 500 | 0.080 |
Why?
|
| Renal Dialysis | 1 | 2015 | 457 | 0.070 |
Why?
|
| Neoplasms, Fibrous Tissue | 1 | 2008 | 1 | 0.070 |
Why?
|
| Pelvic Neoplasms | 1 | 2008 | 2 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 57 | 0.070 |
Why?
|
| Nursing Homes | 2 | 2018 | 8 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 506 | 0.070 |
Why?
|
| Antibodies, Bacterial | 2 | 2018 | 5 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2018 | 46 | 0.060 |
Why?
|
| Prevalence | 2 | 2016 | 259 | 0.060 |
Why?
|
| Seroepidemiologic Studies | 1 | 2024 | 10 | 0.060 |
Why?
|
| Personal Protective Equipment | 1 | 2024 | 4 | 0.060 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 14 | 0.050 |
Why?
|
| Health Personnel | 1 | 2024 | 49 | 0.050 |
Why?
|
| Sepsis | 1 | 2024 | 6 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 268 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 1 | 2023 | 3 | 0.050 |
Why?
|
| Aftercare | 1 | 2023 | 7 | 0.050 |
Why?
|
| Mice | 2 | 2018 | 746 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2023 | 27 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 63 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 118 | 0.050 |
Why?
|
| Animals | 2 | 2018 | 1875 | 0.040 |
Why?
|
| Hygiene | 1 | 2019 | 2 | 0.040 |
Why?
|
| Administration, Intranasal | 1 | 2019 | 4 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2019 | 7 | 0.040 |
Why?
|
| Infection Control | 1 | 2019 | 8 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 58 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 44 | 0.040 |
Why?
|
| Comorbidity | 1 | 2019 | 147 | 0.040 |
Why?
|
| Acinetobacter | 1 | 2018 | 1 | 0.040 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2018 | 1 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2018 | 2 | 0.040 |
Why?
|
| Candida albicans | 1 | 2018 | 6 | 0.040 |
Why?
|
| Bacteria | 1 | 2018 | 9 | 0.040 |
Why?
|
| Biofilms | 1 | 2018 | 3 | 0.040 |
Why?
|
| Bacterial Vaccines | 1 | 2018 | 3 | 0.040 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2018 | 2 | 0.040 |
Why?
|
| Bacterial Infections | 1 | 2018 | 12 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2018 | 5 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2018 | 16 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2018 | 30 | 0.030 |
Why?
|
| Acute Disease | 1 | 2018 | 91 | 0.030 |
Why?
|
| Hospitalization | 1 | 2019 | 128 | 0.030 |
Why?
|
| Vasculitis | 1 | 2017 | 3 | 0.030 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2016 | 1 | 0.030 |
Why?
|
| Vancomycin-Resistant Enterococci | 1 | 2016 | 1 | 0.030 |
Why?
|
| beta-Lactamases | 1 | 2016 | 3 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2016 | 2 | 0.030 |
Why?
|
| Listeria monocytogenes | 1 | 2016 | 3 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2016 | 13 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 41 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2016 | 9 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 64 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 285 | 0.030 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2015 | 1 | 0.030 |
Why?
|
| DNA Transposable Elements | 1 | 2015 | 2 | 0.030 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2015 | 2 | 0.030 |
Why?
|
| Multilocus Sequence Typing | 1 | 2015 | 3 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2015 | 2 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 28 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 18 | 0.030 |
Why?
|
| Gentamicins | 1 | 2015 | 1 | 0.030 |
Why?
|
| Azithromycin | 1 | 2015 | 4 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2015 | 9 | 0.030 |
Why?
|
| Biomarkers | 1 | 2016 | 214 | 0.030 |
Why?
|
| Oropharynx | 1 | 2015 | 2 | 0.030 |
Why?
|
| Skin Diseases, Infectious | 1 | 2015 | 2 | 0.030 |
Why?
|
| Nasal Cavity | 1 | 2015 | 3 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 79 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2017 | 681 | 0.030 |
Why?
|
| Adolescent | 1 | 2017 | 869 | 0.030 |
Why?
|
| Los Angeles | 1 | 2015 | 321 | 0.030 |
Why?
|
| Age Factors | 1 | 2015 | 193 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2013 | 108 | 0.020 |
Why?
|
| Colistin | 1 | 2012 | 1 | 0.020 |
Why?
|
| Bacterial Load | 1 | 2012 | 1 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2012 | 6 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2012 | 5 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 95 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2011 | 14 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2011 | 54 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 12 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2008 | 4 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2008 | 45 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2008 | 197 | 0.020 |
Why?
|